Brisbane, Australia

Mei Kwan Yau


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Brisbane, AU (2015)
  • Brisband, AU (2017)

Company Filing History:


Years Active: 2015-2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Mei Kwan Yau in Protease Activated Receptors

Introduction

Mei Kwan Yau is an accomplished inventor based in Brisbane, Australia. She has made significant contributions to the field of pharmaceutical sciences, particularly in the modulation of protease activated receptors. With a total of 2 patents, her work focuses on developing novel compounds that can be utilized in biological studies and therapeutic applications.

Latest Patents

Mei Kwan Yau's latest patents include innovative compounds aimed at modulating Protease Activated Receptor-2 (PAR2). The first patent, titled "Modulators of protease activated receptors," presents novel compounds of the Formula (I) and pharmaceutical compositions that can be used as tools for biological studies or as agents for treating diseases associated with undesirable PAR2 activity. The second patent, "Modulations of protease activated receptors," similarly provides novel compounds and methods for utilizing these compounds in therapeutic contexts.

Career Highlights

Mei Kwan Yau is affiliated with The University of Queensland, where she conducts her research and development work. Her academic background and research focus have positioned her as a key figure in her field, contributing to advancements in understanding and treating disorders linked to PAR2.

Collaborations

Throughout her career, Mei Kwan Yau has collaborated with notable colleagues, including David P Fairlie and Ligong Liu. These collaborations have enhanced her research efforts and expanded the impact of her innovations.

Conclusion

Mei Kwan Yau's work in the modulation of protease activated receptors represents a significant advancement in pharmaceutical research. Her contributions are paving the way for new therapeutic options in treating diseases associated with PAR2 activity.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…